DESIGN AND CHARACTERISATION OF TRANSDERMAL PATCHES OF PHENFORMIN HYDROCHLORIDE
Objective: In present work was designed to develop suitable transdermal matrix patches of Phenformin hydrochloride using various hydrophilic (HPMC) and hydrophobic (EUDRAGID) polymers as matrix formers.
Methods: Transdermal patches containing Phenformin hydrochloride were prepared by the solvent casting evaporation technique.
Results: Revealed that prepared patches showed good physical characteristics, no drug-polymer interaction and no skin irritation was observed. The in vitro release study revealed that F3 formulation showed maximum release in 24 h. Formulation F3 was subjected for accelerated stability studies. The F3 formulation was found to be stable as there was no drastic change in the Physico-chemical properties of the patches, which was also confirmed by FTIR.Conclusion: Thus conclusion can be made that stable transdermal patches of Phenformin hydrochloride has been developed. F1, F2, F3, F4 formulations showed highest cumulative percentage drug release of 98.13%, 95.50%, 98.65%, 97.21% were obtained during in vitro drug release studies after 24 h. The release of Phenformin hydrochloride appears to be dependent on lipophilicity of the matrix. Moderately lipophillic matrices showed best release. The predominant release mechanism of drug through the fabricated matrices was believed to be by diffusion mechanism. Based upon the in vitro dissolution data the F3 formulation was concluded as optimized formulation.
2. Finnin BC. Transdermal drug delivery-what to expect in the near future. Business Briefing Pharmatech; 2003. p. 192-3.
3. Ghosh TK, Pfister WR. Transdermal and topical drug delivery systems. Int. Pharm, Press; 2012. p. 39.
4. Hadgraft J, Guy R. In: Transdermal Drug Delivery. Marcel Dekker, Inc., New York and Basel; 1991. p. 296.
5. Chein YW. Transdermal drug delivery and delivery system. In: Novel drug delivery system. Vol. 50. Marcel Dekker, Inc., New York; 1992. p. 301-81.
6. Martin A, Swabrik J, Cammarara A. Physical pharmacy. 4th ed. New delhi: B. I Vaverly Pvt Ltd; 1996. p. 264-8.
7. RL Cleek, AL Bunge. A new method for estimating dermal absorption from chemical exposure. General approach Pharm Res 1993;10:497â€“506.
8. Ghosh TK, Jasti BR. editors. Theory and Practice of Contemporary Pharmaceutics. 1st ed. Florida: CRC Press; 2005. p. 423-53.
9. Roberts MS. Targeted drug delivery to the skin and deeper tissues: role of physiology, solute structure and disease. Clin Exp Pharmacol Physiol 1997;24:874-9.
10. Berner B, John VA. Pharmacokinetic characterization of transdermal delivery systems. Clin Pharmacokinetics 1994;26:121â€“34.
11. Schaefer H. Penetration, permeation, and absorption of triamcinolone acetonide in normal and psoriatic skin. Arch Dermatol 1977;258:241â€“9.
12. Ghosh TK. Development of a transdermal patch of methadone: in vitro evaluation across hairless mouse and human cadaver skin. Pharm Dev Technol 1996;1:285â€“91.
13. Gaur KP, Mishra S, Purohit S, Dave K. Transdermal delivery system: a review. Asian J Pharm Clin Res 2009;2:14-20.
14. Kumar Ritesh, Philip Anil. Modified transdermal technologies: Breaking the barriers of drug permeation via the skin. Trop J Pharm Res 2007;6:633-44.
15. Singh PB, Choudhury PK. Penetration enhancers for transdermal drug delivery of systemic agents. J Pharm Res 2007;6:44-50.
16. Guyot M, Fawas F. Design and in vitro evaluation of adhesive matrix for transdermal delivery of propranolol. Int J Pharm 2000;204:171-82.
17. Rao PR, Reddy MN, Ramakrishna S, Diwan PV. Comparative in vivo evaluation of propranolol hydrochloride after oral and transdermal administration in rabbits. Eur J Pharm Biopharm 2003;56:81-5.
18. Manvi FV, Dandagi PM, Gadad AP, Mastiholimath VS. Formulation of a transdermal drug delivery system of ketotifen fumarate. Indian J Pharm Sci 2003;65:239-43.
19. Gupta SP, Jain SK. Effective and controlled transdermal delivery of metoprolol tartarate. Indian J Pharm Sci 2005;67:346-50.
20. Bharkatiya M, Nema RK, Gupta GD, Gaud RS. Designing and evaluation of propranolol hydrochloride transderma patches. Pharma Rev 2005;204:113-6.
21. Das MK, Bhattacharya A, Ghosal SK. Transderma drug delivery of trazodone hydrochloride form acrylic film prepared from aqueous latex. Indian J Pharm Sci 2006;68:41-6.
22. Soni Mohit, Kumar Sandeep, Gupta DR. GD: Transdermal drug delivery: a novel approach to skin permeation. J Pharm Res 2009;2:1184-90.
23. Naik Aarti, Yogeshvar N, Kalia Guy, Richard Guy H. Transdermal drug delivery: overcoming the skinâ€™s barrier function. Pharm Sci Technol Today 2009;3:318-26.
24. Arunachalam A, Karthikeyan, Vinay Kumar D, Prathap M, Sethuraman S, Ashutosh Kumar S, Manidipa S. Transdermal drug delivery system: a review. Curr Pharma Res 2010;1:70-81.
25. Loyd V, Allen Jr, Nicholas G Popovich, Howard C Ansel. Pharmaceutical dosage forms and drug delivery systems. 8th Edition. Wolter Kluwer Publishers, New Delhi; 2005. p. 298-9.
26. Mukherjee B, Mahapatra S, Gupta R, Patra B, Tiwari A, Arora P. A comparison between povidoneethylcellulose and povidone-eudragit transdermal dexamethasone matrix patches based on in vitro skin permeation. Eur J Pharm Biopharm 2005;59:475-83.
27. Arora P, Mukherjee B. Design, development, physicochemical, and in vitro and in vivo evaluation of transdermal patches containing diclofenac diethylammonium salt. J Pharm Sci 2002;91:2076-89.